Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 3/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ADAM10 | O14672 | 3/20 | 0.32 |
| ▸ | MMP1 | P03956 | 3/20 | 0.32 |
| ▸ | MMP2 | P08253 | 3/20 | 0.32 |
| ▸ | MMP3 | P08254 | 3/20 | 0.32 |
| ▸ | MMP7 | P09237 | 3/20 | 0.32 |
| ▸ | MMP9 | P14780 | 3/20 | 0.32 |
| ▸ | MMP8 | P22894 | 3/20 | 0.32 |
| ▸ | MMP13 | P45452 | 3/20 | 0.32 |
| ▸ | MMP14 | P50281 | 3/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 2/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7171906 | 1.00 | NTSR1 (0.40) | NTSR1GRIN2BGRIN2CSMN1; SMN2HSD11B1 | |
| SCHEMBL9734966 | 0.90 | NTSR1 (0.37) | NTSR1GRIN2BGRIN2CSMN1; SMN2HSD11B1 | |
| SCHEMBL14219500 | 0.89 | NTSR1 (0.36) | NTSR1GRIN2BGRIN2CSMN1; SMN2HSD11B1 | |
| SCHEMBL16317418 | 0.87 | NTSR1 (0.35) | NTSR1GRIN2BGRIN2CSMN1; SMN2HSD11B1 | |
| SCHEMBL3053658 | 0.87 | NTSR1 (0.35) | NTSR1GRIN2BGRIN2CSMN1; SMN2HSD11B1 | |
| SCHEMBL16317411 | 0.85 | NTSR1 (0.35) | NTSR1GRIN2BGRIN2CSMN1; SMN2HSD11B1 | |
| SCHEMBL3051772 | 0.85 | NTSR1 (0.35) | NTSR1GRIN2BGRIN2CSMN1; SMN2HSD11B1 | |
| SCHEMBL3164763 | 0.83 | GRIN2B (0.54) | NTSR1GRIN2BGRIN2CSMN1; SMN2HSD11B1 | |
| SCHEMBL16317480 | 0.83 | GRIN2B (0.54) | NTSR1GRIN2BGRIN2CSMN1; SMN2HSD11B1 | |
| SCHEMBL3054791 | 0.82 | NTSR1 (0.40) | NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678765-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2010-03-16 | — | — | US | disclosed |
| US-7678765-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2010-03-16 | — | — | US | disclosed |
| US-7678765-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2010-03-16 | — | — | US | disclosed |
| EP-1294747-B1 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR SA (ES) | 2008-04-30 | — | — | EP | disclosed |
| US-7348310-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2008-03-25 | — | — | US | disclosed |
| US-7348310-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2008-03-25 | — | — | US | disclosed |
| US-7348310-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2008-03-25 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-20040097413-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097413-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, PML, APLNR | NTSR1 3472/4885GRIN2B 2605/4885GRIN2C 3233/4885 |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, APLNR, PAICS | NTSR1 2662/4885GRIN2B 2925/4885GRIN2C 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.